Trends in buprenorphine treatment disparities during the COVID pandemic in Massachusetts

Abstract

Background: Racial, sex, and age disparities in buprenorphine treatment have previously been demonstrated. We evaluated trends in buprenorphine treatment disparities before and after the onset of the COVID pandemic in Massachusetts. Methods: This cross-sectional study used data from an integrated health system comparing 12-months before and after the March 2020 Massachusetts COVID state of emergency declaration, excluding March as a washout period. Among patients with a clinical encounter during the study periods with a diagnosis of opioid use disorder or opioid poisoning, we extracted outpatient buprenorphine prescription rates by age, sex, race and ethnicity, and language. Generating univariable and multivariable Poisson regression models, we calculated the probability of receiving buprenorphine. Results: Among 4,530 patients seen in the period before the COVID emergency declaration, 57.9% received buprenorphine. Among 3,653 patients seen in the second time period, 55.1% received buprenorphine. Younger patients (<24) had a lower likelihood of receiving buprenorphine in both time periods (adjusted prevalence ratio (aPR), 0.56; 95% CI, 0.42–0.75 before vs. aPR, 0.76; 95% CI, 0.60–0.96 after). Male patients had a greater likelihood of receiving buprenorphine compared to female patients in both time periods (aPR: 1.05; 95% CI, 1.00–1.11 vs. aPR: 1.09; 95% CI, 1.02–1.16). Racial disparities emerged in the time period following the COVID pandemic, with non-Hispanic Black patients having a lower likelihood of receiving buprenorphine compared to non-Hispanic white patients in the second time period (aPR, 0.85; 95% CI, 0.72–0.99). Conclusions: Following the onset of the COVID pandemic in Massachusetts, ongoing racial, age, and gender disparities were evident in buprenorphine treatment with younger, Black, and female patients less likely to be treated with buprenorphine across an integrated health system.

Keywords:

• Opioid
• buprenorphine
• disparities
• racial disparities
• opioid use disorder
• sex disparities
• age disparities
• young adults
• female patients
• Black patients

Author contributions

SEW and SGW conceived of the evaluation. NMB, TTH, and CC conducted the data analysis. SEW took the lead in writing the manuscript. SGW, EL, SK, ADC, TTH, CC, and TDS contributed to the interpretation of the data and provided critical feedback, and contributed to the writing of the manuscript.

Disclosure statement

Dr. Wakeman previously served on the Clinical Advisory Board for Celero Systems. For the remaining authors, none were declared.